Abstract: The invention is generally directed to a physiogenomic method for predicting diabetes and metabolic syndromes induced by psychotropic drugs. In one embodiment, the invention relates to the use of genetic variants of marker genes to predict the likelihood that an individual will experience undesirable metabolic side effects as a result of the use of a drug including, but not limited to, psychotropic drugs. The invention also relates to methods predicting the likelihood of diabetes and metabolic syndromes induced by the use of drugs with undesirable metabolic side effects.

Abstract: Disclosed herein are compositions and methods relevant to a novel Drug Metabolism Reserve Physiotype to determine the metabolic capacity of a human individual. The Drug Metabolism Reserve Physiotype allows the determination of the innate metabolic capacity of the patient relevant to antidepressant and stimulant treatment and can be predicted and diagnosed simply from a blood sample. In the disclosed method, an individual is genotyped for a plurality of polymorphisms in a gene encoding CYP2C9, a gene encoding CYP2C19 and a gene encoding CYP2D6, and the genotypes are used to produce four novel indices, which relate to the metabolic capacity of the human individual.

Abstract: A physiogenomics method for predicting an individual's response to an environmental stimulus comprises producing and recording a physiogenomic model. The model is produced b a method including selecting a plurality of genetic markers, identifying significant covariates among demographic data to produce correlated markers for use as a covariate in an unadjusted association test; performing for the plurality each selected genetic markers an unadjusted association test; using permutation testing to select a plurality of model building markers; identifying one or more genes not associated with a particular outcome in the individual to serve as a physiogenomic control; and presenting a display of the individual's predicted physiological response. One can then compare the genetic markers of the individual to the physiogenomic database and convey to the individual an appropriate treatment intervention.

Abstract: Disclosed herein are genetic markers related to the efficacy and/or safety of thiazolidinedione therapy identified by a physiogenomic methodology that correlates the genetic markers with a physiological response. The genetic markers described herein were not previously associated with the efficacy and/or safety of thiazolidinedione therapy. The markers related to safety are those associated with the important side effects of BMI increase and development of edema. In one embodiment, markers related to efficacy of thiazolidinedione therapy are associated with glycosylated hemoglobin. Method of assessing an individual for markers associated with the safety and/or efficacy of thiazolidinedione therapy are described.

Abstract: The invention is generally directed to a physiogenomic method for predicting diabetes and metabolic syndromes induced by psychotropic drugs. In one embodiment, the invention relates to the use of genetic variants of marker genes to predict the likelihood that an individual will experience undesirable metabolic side effects as a result of the use of a drug including, but not limited to, psychotropic drugs. The invention also relates to methods predicting the likelihood of diabetes and metabolic syndromes induced by the use of drugs with undesirable metabolic side effects.

Abstract: The present invention relates to the use of genetic variants of associated marker genes to predict an individual's response to exercise. The present invention further relates to analytical assays and computational methods using the novel marker gene set. The present invention has utility for developing personalized fitness regimens to optimize physiological response.

Abstract: The present invention relates to the use of genetic variants of associated marker genes to predict an individual's response to diet. The present invention further relates to analytical assays and computational methods using the novel marker gene set. The present invention has utility for developing personalized diet regimens to optimize physiological response, including changes in body mass index (BMI) and blood lipid and triglyceride levels.

Abstract: Disclosed are methods for identifying nucleic acids in a sample of nucleic acids in which nucleic acids are initially present in unequal amounts. The methods include partitioning the starting population of nucleic acids to form one or more subpopulations, and then identifying nucleic acids that are present in different amounts in the partitioned nucleic acid sample as compared to the starting population.

Abstract: A physiogenomic-based method for predicting the outcome of treatment regimens in human patients based upon association screening to identify genetic markers and related physiological characteristics that influence the disease status of a patient, the progression to disease and response to the treatment. By repeating the analysis quantitatively for each of multiple treatment regimens, a profile can be created for each patient to determine which of several treatment regimens are best suited to the patient's clinical needs.

Abstract: Methods, computer program(s) and database(s) to analyze and make use of gene haplotype information. These include methods, program, and database to find and measure the frequency of haplotypes in the general population; methods, program, and database to find correlation's between an individual's haplotypes or genotypes and a clinical outcome; methods, program, and database to predict an individual's haplotypes from the individual's gen type for a gene; and methods, program, and database to predict an individual's clinical response to a treatment based on the individual's genotype or haplotype.

Abstract: A system and method is disclosed for managing users' genomic data, including providing and offering access to genomic-based services, routing genomic data to providers of genomic-based services, brokering financial transactions related to the management of genomic data, securing for users best prices for genomic-based services, allowing users to earn money for the use of their genomic and other data, and using genomic data for marketing and developing products in particular geographic regions or for particular populations.

Abstract: Disclosed are methods for identifying nucleic acids in a sample of nucleic acids in which nucleic acids are initially unequal amounts. The methods include partitioning the starting population of nucleic acids to form one or more subpopulations, and then identifying nucleic acids that are present in different amounts in the partitioned nucleic acid sample as compared to the starting population. Also disclosed are methods of generating databases based on sizes of DNA fragments and size-based sequencing of those fragments.

Abstract: Methods, computer programs and databases for determining haplotypes from a collection of polymorphisms are provided. These include methods, programs, and databases to find and measure the frequency of haplotypes in the general population; and methods, programs, and databases for predicting an individual's haplotypes from the individual's genotype for a gene.

Abstract: Disclosed are methods for identifying nucleic acids in a sample of nucleic acids in which nucleic acids are initially present in unequal amounts. The methods include partitioning the starting population of nucleic acids to form one or more subpopulations, and then identifying nucleic acids that are present in different amounts in the partitioned nucleic acid sample as compared to the starting population.